621 Treatment of HCV Recurrence After Liver Transplant: A Review of Early Virologic Responses Using Telaprevir, A Single Center Experience of 24 Patients

two groups were compared using independent-samples t-test. Survival analysis and the distributions were calculated using Kaplan-Meier method and Mantel-Cox log-rank test. Results: Out of total 43 combined liver-kidney transplants, 30 SLK cases (24 post-MELD and 6 pre-MELD) were included. Proportions of age, gender, ethnicity, pre-transplant MELD score; pre-transplant renal replacement therapy requirement, hypertension, diabetes mellitus and follow-up period were similar in two groups. Median follow up period was 30 months. Both overall and kidney-graft survival in pre-MELD era were 50%, but improved to 91.7% in post-MELD era (p=0.02). When compared according to HCV diagnosis, there was no statistical significance in overall and kidney-graft survival between 9 HCV and 15 non-HCV groups in post-MELD era (p=0.67 and p=0.4, respectively). Conclusion: Literature suggests lower risk of liver graft loss in SLK compared to LTA, but not much information is available regarding the specific diagnosis of the underlying liver disease, HCV vs non-HCV.Our study demonstrated that overall and kidney graft survival has significantly improved post-MELD as compared to pre-MELD era. Additionally, our study showed that there was no statistical difference in overall and kidney-graft survival between HCV and non-HCV groups. This observation needs to be further studied and verified in larger cohort to fully identify the impact of Hepatitis C infection on liver and kidney grafts, post transplantation.